scholarly journals Halting coronavirus polymerase

2020 ◽  
Vol 295 (15) ◽  
pp. 4780-4781 ◽  
Author(s):  
Robert N. Kirchdoerfer

The nucleotide analogue remdesivir is an investigational drug for the treatment of human coronavirus infection. Remdesivir is a phosphoramidate prodrug and is known to target viral RNA-dependent RNA polymerases. In this issue, Gordon et al. identify that remdesivir acts as a delayed RNA chain terminator for MERS-CoV polymerase complexes.

2020 ◽  
Vol 13 (11) ◽  
Author(s):  
Franca del Nonno ◽  
Andrea Frustaci ◽  
Romina Verardo ◽  
Cristina Chimenti ◽  
Emanuele Nicastri ◽  
...  

2013 ◽  
Vol 433 (2) ◽  
pp. 92-94
Author(s):  
Qiang Wang ◽  
Leiyun Weng ◽  
Hongbing Jiang ◽  
Shijian Zhang ◽  
Tetsuya Toyoda

Intervirology ◽  
2006 ◽  
Vol 50 (2) ◽  
pp. 71-77 ◽  
Author(s):  
Apiradee Theamboonlers ◽  
Rujipat Samransamruajkit ◽  
Chittima Thongme ◽  
Alongkorn Amonsin ◽  
Voranush Chongsrisawat ◽  
...  

2020 ◽  
Author(s):  
Shahan Mamoor

The coronavirus COVID19 pandemic is an emerging biosafety threat to the nation and the world (1). There are no treatments approved for coronavirus infection in humans (2) and there is a lack of information available regarding the basic transcriptional behavior of human cells and mammalian tissues following coronavirus infection. We mined two independent datasets (3, 4), public (3) and published (4) containing transcriptome data from infection models of the Middle East respiratory syndrome (MERS) coronavirus and human coronavirus (HCoV) to discover genes that are differentially expressed in coronaviruses and identify potential therapeutic targets and host cell vulnerabilities. We identified the La ribonucleoprotein domain family member 6 (LARP6) as a conserved differentially expressed gene following coronavirus infection. LARP6 may be involved in the cellular response to COVID19 infection.


Author(s):  
I. E. Khoroshilov

The new coronavirus infection COVID-19 that appeared at the end of 2019 is signifi cantly different from the viral infections that existed previously. The new SARS-CoV-2 coronavirus combines two transmission routes—aerosol and oral-intestinal. The targets for this virus are both cells of the respiratory system and the human gastrointestinal tract. Along with the classical form of this disease, the so-called “gastrointestinal” form is described, in which the clinical picture is dominated by signs of damage to the gastrointestinal tract (diarrhea, vomiting, anorexia). These symptoms are detected, in general, in 20% of patients with COVID-19. More than 80% of patients have mild forms, a third of these individuals had diarrhea. Although SARSCoV-2 viral RNA is detected in faeces samples of patients with COVID-19, it does not carry an infectious onset, and not a single case of fecal-oral transmission has been confi rmed. Since the intestines are the most powerful organ of our immune system, we can introduce SARS-CoV-2 viral RNA into the gastrointestinal tract to ensure the formation of immunity to this infection.


2002 ◽  
Vol 324 (1) ◽  
pp. 47-62 ◽  
Author(s):  
Alexander E Gorbalenya ◽  
Fiona M Pringle ◽  
Jean-Louis Zeddam ◽  
Brian T Luke ◽  
Craig E Cameron ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document